A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate.
To elucidate the mechanism of propofol-induced pain on injection, we performed several studies using nafamostat mesilate, a kallikrein inhibitor, or lidocaine. As both pretreatment and low-dose mixing with nafamostat produced the same effects on pain reduction, we used the latter method in the following experiments. Low-dose mixing had the same effect on injection pain as mixing with lidocaine. The extent of pain was assessed by measuring bradykinin concentrations by mixing with blood. Propofol and its lipid solvent mixed with blood produced approximately two-fold generation of bradykinin compared with the saline control, and this was inhibited completely by nafamostat and lidocaine. Injection of the lipid solvent before propofol significantly aggravated pain compared with prior injection of saline, although the lipid solvent injected twice caused no change in pain. These results suggest that the lipid solvent for propofol activates the plasma kallikrein-kinin system and produces bradykinin which modifies the injected local vein. This modification of the peripheral vein may increase the contact between the aqueous phase propofol and the free nerve endings of the vessel, resulting in aggravation of propofol-induced pain.
Nakane
M
M
Department of Anaesthesiology, Central Aizu General Hospital, Aizuwakamatsu City, Japan.
Iwama
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018686:Anesthetics, Intravenous / Q000009:adverse effects*; D000779:Anesthetics, Local / Q000627:therapeutic use; D001550:Benzamidines; D001920:Bradykinin / Q000096:biosynthesis; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced* / Q000517:prevention & control; D015742:Propofol / Q000009:adverse effects*; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D013696:Temperature
D018686:Anesthetics, Intravenous; D000779:Anesthetics, Local; D001550:Benzamidines; D006146:Guanidines; D015842:Serine Proteinase Inhibitors; D008012:Lidocaine; D007610:Kallikreins; D001920:Bradykinin; C032855:nafamostat; D015742:Propofol